Please select the option that best describes you:
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
Answer from: Medical Oncologist at Academic Institution
The data supporting use of neratinib for patients whose breast cancers have activating HER2 mutations is in the metastatic setting (https://www.ncbi.nlm.nih.gov/pubmed/37597578). Neratinib use in the adjuvant setting for breast cancer requires that there be HER2 amplification by IHC or FISH.
Sign in or Register to read more